TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: laryngeal conditions of intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Anxiety Visual Analog Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scale for the assessment and rating of ataxia (SARA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prehension force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tuned fork result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma control level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in YMRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SIGH-D Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival rate at 2 months
Endpoint domain: Mortality/survival
Primary endpoint: First access success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Rhinitis Quality of Life Questionnaire (RQLQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient-ventilator synchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Spirometry results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Testosterone <=0.5 Nanogram/Milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lung Function FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SOT equilibrium scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPD symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin dilution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence/absence of anal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Subjective Seal Leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Seal Leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of defined sexual risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: high specific troponin T (hs-TrT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Creatin-Phosphokinase (CK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Creatinkinase Muscle- Brain (CK-MB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Agoraphobia Ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Panic Attack Frequency Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Internal Sensation Anxiety Ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving PGA clear (0) or minimal (1) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving a > PASI 50 clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving a > PASI 75 clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Assessed by Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acetabular cup angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Change in Cone Spacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in renal resistive index (RRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Response rate to revaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of protective titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metabolic state of the intestine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Objective Response Rate (ORR) in the Intent-to-treat (ITT) Analysis Set
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (ORR) in the Per-protocol Analysis Set (PPAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Biopsy Confirmed AMR
Endpoint domain: Adverse events/effects
Primary endpoint: Standard Deviation of the Lateral Position (SDLP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burning mouth syndrome severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-thaw oocyte survival rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hospitalisations and deaths due to pertussis
Endpoint domain: Mortality/survival
Primary endpoint: Fetal wellbeing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Response Rate (Complete and Partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Events of special interest (ESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in log10 HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pepsinogen value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Implant migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: toxicity profile of 11C-Choline administration
Endpoint domain: Adverse events/effects
Primary endpoint: biochemical recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Functional independence as defined by modified Rankin Scale (mRS) score ≤ 2 at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial recanalization of the occluded target vessel measured by TICI score equal or superior to 2b
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systematic ICH with 24 ±3hrs post procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of First Fall or Death
Endpoint domain: Mortality/survival
Primary endpoint: Liver fibro-inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complicated grief symptom change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy of ATN-224 and bortezomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extubation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neuropsychological function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of OFF time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: progression free rate of first-line treatment with erlotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Acceptability Comparison of CICU TALC by CICU Providers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant Retention Rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Summary Rating of CICU TALC Intervention by Parent Participants
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in serum concentration of 25-hydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjective nasal breathing impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in placebo corrected 6-minute walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving renal complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: resolution of Bronchopleural Fistulae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in psychological stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Concentration-time Curve of the Analyte in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of the Analytes (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of genetic counseling sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pharmacokinetic profile (AUClast, Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ejection fraction of the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neuropsychological variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adverse Event assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Distance walked during the six minutes walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in steroid profile in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in new steroid profile markers in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in new steroid profile markers in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Ethyl glucuronide in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Ethyl sulfate in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 10 Meter Walking at Preferred Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 Meter Walking at Maximal Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation from a Prescribed Ophthalmic Drop Regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Response Rate at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral tissue oxygenation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral blood flow changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total urine output production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of participants with real world safety events
Endpoint domain: Adverse events/effects
Primary endpoint: WF-OCT image acquisition quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of AV synchrony at maximum exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants That do Not Experience Rash
Endpoint domain: Adverse events/effects
Primary endpoint: Mean pain score during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extended Rapid Virologic Response (eRVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response (SVR24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Score of Attention and Executive Functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change of ability to awaken
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Efficacy of Inhaled Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACLS Megacode Examination Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Data completion rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: days to achieve full tolerated feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microscan at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluate the Effect of LMIS 50 mg on Cardiovascular Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum transferrin receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neural activity assessed by BOLD fMRI during anticipation of social feedback
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neural activity assessed by BOLD fMRI during consummation of social feedback
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PK parameters from plasma concentration versus time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total radioactivity recovery data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in agility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Carotid Intima-media Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Were Neutralising Antibody (NAb) Positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantification of BCG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ability of a child's physical function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Change in cardiovascular disease knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in perceived efficacy in patient-physician interaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in health literacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: CT Scan for Fusion Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma related exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of Participants Receiving Drug/Dose Modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Grade 3 or Higher TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Serious TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: gene expression profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HMO composition and concentration in maternal blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HMO composition and concentration in fetal blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HMO composition and concentration in maternal urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HMO composition and concentration in colostrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With an Increase/Improvement in Focusing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Resilience level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Medical tool effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney cancer progression
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Study Eye Mean Diurnal IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: 2HG Concentration via 3T MRI Scanner
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2HG Concentration from tissue samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of secondary pulmonary hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prognosis of secondary pulmonary hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of Intraoperative Neuromonitoring (IONM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound Dehiscence or Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Success of implant placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quality of Parent-teen Communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Metabolic health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neurocognitive development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiovascular and vascular health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: endometrial thickness change towards baseline (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of any Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: ADV and/or CMV reactivations
Endpoint domain: Adverse events/effects
Primary endpoint: Total Amount of Slow Wave Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Number of complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamstring length measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Real-World Progression-Free Survival (rwPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Real-World Time to Tumor Progression (rwTTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Self-harm Ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: longevity of monolithic zirconia restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with HCV Ab+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with HBsAg+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with HIV Ab+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Weight change from baseline to 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight change from baseline to 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in Inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Treatment Emergency Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Severe TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: GnRH-stimulated LH Level ≤3 IU/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total dose of morphine used
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Composite of Major Adverse Events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Primary Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change from baseline in Health Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status